XML 68 R4.htm IDEA: XBRL DOCUMENT v3.20.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Revenues      
Revenues $ 5,633 $ 24,291 $ 3,708
Costs and expenses      
Research and development (including stock compensation expense of $2,217, $1,609 and $1,232 in 2019, 2018 and 2017, respectively) 39,045 38,656 27,841
General and administrative (including stock compensation expense of $2,634, $2,240 and $1,812 in 2019, 2018 and 2017, respectively) 11,378 10,442 8,466
Depreciation 698 855 684
Total costs and expenses 51,121 49,953 36,991
Gain from insurance proceeds, net 0 617 0
Loss from operations (45,488) (25,045) (33,283)
Income from change in fair value of warrants, net 0 0 728
Other income, net 906 762 314
Net loss and comprehensive loss $ (44,582) $ (24,283) $ (32,241)
Net loss per common share, basic and diluted (in dollars per share) $ (0.29) $ (0.18) $ (0.29)
Weighted average shares outstanding, basic and diluted (in shares) 151,696 136,641 112,053
Royalty and other contract revenue      
Revenues      
Revenues $ 0 $ 1,461 $ 1,925
Grant revenue      
Revenues      
Revenues 116 554 865
Healios | Contract revenue      
Revenues      
Revenues $ 5,517 $ 22,276 $ 918